STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March
- First patient dosed in Phase I clinical study of ATOR-1015.
- New preclinical data presented demonstrating strong anti-tumor effects for the 4-1BB antibody ATOR-1017.
- Alligator Bioscience launched RUBY™, a novel concept in bispecific antibody formats.
Events after the end of the period
- Tumor-localizing properties of ATOR-1015 demonstrated by live imaging.
- New preclinical data for ATOR-1144 demonstrates potential for activation of both the innate and the adaptive immune system as well as direct anti-tumor effects.
Financial information
January-March 2019
- Net sales, SEK 0.0 million (0.8)
"This is a very exciting year for Alligator. We currently have two projects – ADC-1013 and ATOR-1015 – in clinical development. These projects will soon be joined by ATOR-1017," CEO Per Norlén comments.
Read the complete report in the pdf below.
The information was submitted for publication at 8:00 a.m. CEST on April 17, 2019.
For further information, please contact:
Per Norlén
CEO
per.norlen@alligatorbioscience.com
046-540-82-00
Per-Olof Schrewelius
CFO
per-olof.schrewelius@alligatorbioscience.com
046-540-82-03
Cecilia Hofvander
Director IR & Communications
cecilia.hofvander@alligatorbioscience.com
046-540-82-06
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
Phone +46-46-540-82-00
www.alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit www.alligatorbioscience.com.
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Alligator Bioscience AB (publ) Interim report January-March 2019 |
View original content:http://www.prnewswire.com/news-releases/alligator-bioscience-ab-publ-interim-report-january-march-2019-300833596.html
SOURCE Alligator Bioscience
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.